From the Desk of the CEO

Patients with diabetes who used statins experienced less control of their diabetes than patients who did not take statins, suggests a new retrospective study published in JAMA Internal Medicine.

Between 2019 and 2020, illicitly manufactured fentanyl-related overdose deaths increased substantially in western, southern, and midwestern states, CDC reported.

FDA said it is temporarily halting its risk evaluation and mitigation strategy (REMS) program for clozapine, a treatment for schizophrenia.

The Pharmacy Technician Certification Board (PTCB) announced the launch of a new certificate in MTM for pharmacy technicians.

This year has seen the approval of 2 new biosimilar drugs, including the first biosimilar to earn FDA’s “interchangeable” designation. Byooviz (ranibizumab-nuna) is biosimilar to Lucentis (ranibizumab), a drug for neovascular (wet) age-related macular degeneration (nAMD). Semglee (insulin glargine-yfgn), the first such drug to earn the “interchangeable” distinction, is biosimilar to Lantus (insulin glargine) for diabetes.